Perspective Therapeutics, Inc. (CATX) Cash Flow Statement
Perspective Therapeutics, Inc. (CATX) generated -$93.1M of operating cash flow over the twelve months to 2026-06-30, spent $28.2M on capital expenditure and had free cash flow of -$121.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CATXPerspective Therapeutics, Inc.Follow CATX — free
—
Price chart with a free account
- Market cap
- 183.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2012 Jun 12 | FY2013 Jun 13 | FY2014 Jun 14 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Jun 20 | FY2021 Jun 21 | FY2022 Jun 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.4 | -3.1 | -3.2 | -3.5 | -3.9 | -5.7 | -5.7 | -5.0 | -3.6 | -2.8 | -7.7 | -36.9 | -18.3 | -82.5 | -93.1 | |
| Capital expenditure | 0.1 | 0.0 | 0.0 | 0.1 | 0.5 | 0.5 | 0.3 | 0.4 | 0.3 | 0.4 | 0.3 | 1.1 | 54.5 | 12.9 | -28.2 | |
| Free cash flow | -2.5 | -3.1 | -3.2 | -3.7 | -4.4 | -6.3 | -6.0 | -5.5 | -3.9 | -3.2 | -8.0 | -38.0 | -72.8 | -95.4 | -121.3 | |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | — | |
| Stock-based compensation | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 1.1 | 3.7 | 5.4 | 9.0 | — |
USD millions · SEC XBRL
Perspective Therapeutics, Inc. — questions
- What is Perspective Therapeutics, Inc.'s operating cash flow?
- -$93.1M over the twelve months to 2026-06-30.
- How much does Perspective Therapeutics, Inc. spend on capital expenditure?
- $28.2M over the twelve months to 2026-06-30.
- What is Perspective Therapeutics, Inc.'s free cash flow?
- -$121.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Perspective Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.